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Summary
 
Bad is a distant relative of Bcl-2 and acts to promote cell death. Here, we show that Bad ex-
pression levels are greatly increased in thymocytes during apoptosis. We generated 
 
bad
 
 trans-
genic mice to study the action of upregulated Bad expression on T cell apoptosis. The T cells
from these mice are highly sensitive to apoptotic stimuli, including anti-CD95. The numbers
of T cells are greatly depleted and the processes of T cell development and selection are per-
turbed. We show that the proapoptotic function of Bad in primary T cells is regulated by Akt
kinase and that Bad overexpression enhances both cell cycle progression and interleukin 2 pro-
duction after T cell activation. These data suggest that Bad can act as a key regulator of T cell
apoptosis and that this is a consequence of its upregulation after exposure to death stimuli.
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A
 
poptosis plays a crucial role in the development and
maintenance of an efficient immune system. The de-
velopment of T cells in the thymus is characterized by the
production of large numbers of immature thymocytes that
are then subjected to stringent selection criteria. These im-
mature thymocytes undergo random rearrangement of
their T cell receptor genes and display the successfully rear-
ranged protein products on their surfaces. Some of these
cells are then positively selected based on the appropriate
specificity of their T cell receptors and further differentiate
(1). The remaining cells, up to 95% of the CD4
 
1
 
CD8
 
1
 
 T
cell precursors, die by apoptosis, due to either negative se-
lection, as a consequence of expressing self-reactive recep-
tors, death by neglect, or as a result of the failure to receive
any selection signals (2).
One of the first regulators of apoptosis to be identified
was Bcl-2, which is now known to be part of a family of
related proteins (3, 4). Overexpression of 
 
bcl-2
 
 leads to the
inhibition of cell death (5), although there are some apop-
totic pathways that are unaffected by 
 
bcl-2
 
 expression, such
as the CD95-mediated pathway (6). The family of Bcl-2 re-
lated proteins can be divided into two groups based on their
ability to promote or inhibit apoptosis. Promoters include
Bax, Bak, Bik, etc., whereas inhibitors include such proteins
as Bcl-2 itself, Bcl-x
 
L
 
, and Mcl-1 (7). The homology be-
tween family members differs greatly, although all members
possess at least one of four motifs termed Bcl-2 homology
(BH)
 
1
 
 domains (8). The physiological role of Bcl-2 as a reg-
ulator of apoptosis has been closely studied in the processes
of T cell development and selection. Gain of function stud-
ies overexpressing a 
 
bcl-2
 
 transgene in vivo show protection
of immature thymocytes from a variety of death stimuli as
well as increased numbers of mature T cells (9–13).
More recently discovered members of the Bcl-2 family
are less well characterized than the founder member, Bcl-2.
One such protein is Bad, which was first isolated on the ba-
sis of its interaction with Bcl-2 (14). Bad contains 204
amino acids and has only limited homology to other Bcl-2
family members. It is widely expressed in many tissues and
in cell types (15). Bad was shown to interact selectively
with Bcl-x
 
L
 
 and to a lesser extent, Bcl-2, but not to form
homodimers. Overexpression of Bad in an IL-3–dependent
cell line showed it to be proapoptotic, acting by having an
antagonistic effect on the death-repressing activity of Bcl-x
 
L
 
.
However, the overexpression of Bad alone or with Bcl-2
 
1
 
Abbreviations used in this paper:
 
 BH, Bcl-2 homology; HA, hemagglutinin;
LCR, locus control region; PI-3-K, phosphatidylinositide-3-kinase;
RAG-1, recombination activation gene 1. 
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did not have any significant effect, suggesting that the ac-
tion of Bad is dependent on heterodimerization (14). Re-
cent studies have indicated the presence of a BH3 domain
in Bad that is essential for heterodimerization and apoptotic
activity (16–18). Moreover, mutant Bcl-2 and Bcl-x
 
L
 
 mol-
ecules that have lost the ability to bind Bax are still able to
interact with Bad, suggesting a different mechanism of het-
erodimerization between Bad and other molecules (16, 18).
Bad is found in the cytosol and becomes phosphorylated
on serine 112 or serine 136 after stimulation of an IL-3–
dependent cell line by IL-3 (19, 20). Phosphorylation of Bad
leads to its sequestration by an isoform of the 14-3-3 pro-
tein in the cytosol. Bad bound to 14-3-3 is inactive since it
can no longer bind Bcl-x
 
L
 
, resulting in enhanced cell sur-
vival (19, 21). The kinase responsible for phosphorylation
of at least one of the Bad serine residues has now been
identified as Akt/PKB (22, 23). Akt is a serine/threonine
kinase which acts downstream of the lipid kinase phos-
phatidylinositide-3-kinase (PI-3-K) (24). Akt phosphory-
lates Bad on a site that is required for its interaction with
14-3-3 (23). Datta et al. showed that this site is serine 136.
They also demonstrated that Akt overexpression can pre-
vent Bad-induced cell death of neurons, which suggests
that Akt-dependent cell survival is mediated in part by
phosphorylation of Bad (22).
To investigate the role of Bad in primary T cells, we ex-
amined Bad expression in thymocytes after exposure to apop-
totic stimuli and found the level of Bad to be greatly upreg-
ulated. To examine the functional consequences of this
Bad overexpression in more detail we generated mice ex-
pressing a 
 
bad
 
 transgene in their T cells. These mice have
severely depleted numbers of T cells and the remaining T
cells are highly sensitive to apoptotic stimuli such as 
 
g
 
-radi-
ation, dexamethasone, and CD95. 
 
bad
 
 transgenic mice with
a unique TCR on a recombination activation gene 1
(RAG-1)
 
2
 
/
 
2
 
 background were found to have highly per-
turbed T cell selection. We demonstrate that the proposed
regulation of Bad function by the PI-3-K/Akt pathway also
operates in primary T cells. As a consequence of elevated
Bad expression, Akt kinase activity is much higher in T
cells from 
 
bad
 
 transgenic mice, these cells also show en-
hanced cell cycle progression and produce greater amounts
of IL-2 in response to activation by anti-CD3. Our data
highlight both the proapoptotic function of Bad within a
physiological context and the consequences of Akt/Bad
regulation for other processes such as cell cycle progression
and cytokine production.
 
Materials and Methods
 
Generation of Transgenic Mice.
 
The hemagglutinin (HA) 
 
bad
 
mouse cDNA (14) was cloned into the polylinker EcoRI site of
the VA hCD2 expression cassette (25). The SalI-XbaI fragment
containing the 
 
bad
 
 transgene was then purified and microinjected
into CBA 
 
3
 
 C57 Bl/10 fertilized oocytes. Transgenic founder
animals were identified by Southern blotting of DNA from tail
biopsies and bred to C57 Bl/10 mice to generate lines that were
maintained as heterozygotes.
 
Western Analysis.
 
Thymocyte whole cell lysates (10
 
7
 
 cells per
lane) were immunoblotted using enhanced chemiluminescence
(Amersham Corp.) for detection. The goat polyclonal anti-Bad
antibody (C20)-G was purchased from Santa Cruz Biotech., the
mouse monoclonal anti-HA antibody (12CA5) from Boehringer
Mannheim, and the anti-Tubulin antibody from SeroTec.
 
Apoptosis Assays and FACS
 
®
 
 Analysis.
 
Single-cell suspensions
were prepared from thymuses in complete medium (RPMI, 50
 
m
 
M 2-ME, 10% FCS). 5 
 
3
 
 10
 
5
 
 cells were plated either untreated
or exposed to dexamethasone (5 
 
m
 
M, Sigma Chemical Co.),
 
g
 
-irradiation (5 Gy), or anti-CD95 antibody (1 
 
m
 
g/ml, Jo2;
PharMingen), and then incubated at 37
 
8
 
C. At each time point,
duplicate aliquots were processed to determine the percentage of
cells undergoing apoptosis. Cells were centrifuged at 1,200 rpm,
washed once in PBS, and stained with propidium iodide in a hy-
potonic buffer at 4
 
8
 
C, then analyzed using flow cytometry as de-
scribed in Nicoletti et al. (26). For FACS
 
®
 
 analysis, single cell sus-
pensions were prepared from thymuses/spleens in air-buffered
IMDM and staining and analysis were carried out as previously
described (27). LY294002 and wortmannin were purchased from
Sigma Chemical Co. and both were dissolved in DMSO before use.
The following mAbs and second layer reagents were used:
FITC-conjugated YTS169.4 (anti-CD8
 
a
 
) (28), phycoerythrin-
conjugated anti-CD4 (Sigma Chemical Co.), biotin-conjugated
KT11 (anti-V
 
b
 
11) (29), FITC-conjugated anti–TCR-
 
d
 
 (GL3),
and streptavidin red 670 (GIBCO BRL).
 
Akt Kinase Assay.
 
The Akt kinase assay was carried out es-
sentially as described in del Peso et al. (23). Akt was immunopre-
cipitated with polyclonal anti-Akt1 (Santa Cruz Biotech.), the
immunocomplexes were collected with protein A–Sepharose
beads, and Akt kinase activity was assayed by an in vitro kinase
reaction containing [
 
g
 
-
 
32
 
P]ATP and histone H2B (Boehringer
Mannheim) as substrate. The products of the reaction were re-
solved by SDS-PAGE and transferred to nitrocellulose filters for
quantification by PhosphorImaging (Molecular Dynamics).
 
Quantitation of T Cell IL-2 Production.
 
Single cell suspensions
were prepared from lymph nodes and then purified using nonad-
hesive nylon wool. Purity was determined using flow cytometry.
Cells were stained for CD3 and the percentage of T cells present
was always 
 
.
 
90%. Plates were precoated with serially diluted
anti-CD3 antibody (2C11). 2 
 
3
 
 10
 
5
 
 cells were plated on pre-
coated wells in complete medium and incubated at 37
 
8
 
C for 48 h.
Supernatant was then collected and incubated with IL-2–depen-
dent CTLL cells (10
 
4
 
/well) for 24 h at 37
 
8
 
C, and then 1 
 
m
 
Ci
[
 
3
 
H]thymidine was added per well and cultures were incubated
for 12 h. Cultures were harvested using a Skatron Micro96 Har-
vester and the amount of [
 
3
 
H]thymidine incorporated was deter-
mined by scintillation counting on a Wallac 1205 Betaplate.
 
Results
 
Bad Is Greatly Upregulated during Thymocyte Apoptosis.
 
To study the action of Bad, we first determined the effect
of apoptosis on Bad expression levels in thymocytes. Thy-
mocytes were taken from C57 Bl/10 mice and cultured for
5 h, either unstimulated or after exposure to 10 Gy of 
 
g
 
-radi-
ation or incubation with 5 
 
m
 
M dexamethasone. The level
of apoptosis induced in the thymocytes was determined us-
ing flow cytometric analysis following cell lysis in a hypo-
tonic buffer and DNA staining by propidium iodide (26).
Equivalent numbers of thymocytes were loaded in each
track for immunoblot analysis and the Western blot was 
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probed with a polyclonal antibody specific for Bad. To de-
termine the level of Bad in normal thymocytes, cells were
frozen immediately after removal from the thymus (Con-
trol, 0 h in Fig. 1). As shown in Fig. 1, the level of Bad in
normal thymocytes is very low, although there is a massive
induction of Bad as thymocytes enter apoptosis particularly
in response to strong apoptotic stimuli such as dexametha-
sone and 
 
g
 
-radiation. This suggests that Bad induction is
concomitant with apoptosis in primary thymocytes and
may well play an important regulatory role. To investigate
this hypothesis further and to study the action of Bad in
primary cells, we decided to establish lines of transgenic
mice overexpressing Bad exclusively within their T cells.
 
Generation and Characterization of Mice Transgenic for bad.
 
Mice were generated bearing a transgene with the mouse
 
bad
 
 cDNA linked to a HA epitope under the control of the
human CD2 promoter and locus control region (LCR)
(Fig. 2 A). The 
 
bad
 
 transgene is targeted to the T cell lineage
in both thymus and periphery (30, 31). The HA-tagged Bad
protein produced by the transgene can be distinguished
from the endogenous Bad protein using the mAb 12CA5
(32).
The level of HA Bad expression in T cells was examined
by Western blot analysis of total cell extracts prepared from
the thymuses of two independent lines of transgenic mice.
Equal amounts of protein were loaded in each lane and ex-
pression was detected with either the 12CA5 monoclonal
(Fig. 2 B) or a polyclonal antibody against Bad (Fig. 2 C).
HA Bad was only detected in thymocytes from transgenic
mice (Fig. 2 B). In a replicate filter probed with the anti-
Bad antibody, both endogenous Bad and transgenic HA
Bad were detected (Fig. 2 C). Endogenous Bad expression
is seen only in the thymocytes from nontransgenic mice.
The highly expressed transgenic HA Bad is represented by
the broader band seen in the transgenic lanes. The size of
the transgenic protein is greater than that of the endoge-
nous protein due to the additional 11 amino acids of the
HA epitope. Therefore, we have established lines of trans-
genic mice that have upregulated levels of Bad expression
in their T cells in a manner analogous to that found in thy-
mocytes after exposure to apoptotic stimuli.
 
bad Transgenic Mice Have Depleted Numbers of T Cells.
 
We analyzed the 
 
bad
 
 transgenic mice to look at the conse-
quences of overexpressing 
 
bad
 
 within their T cells. In two
independent lines of 
 
bad
 
 transgenic mice, 
 
bad
 
 line 1 and 
 
bad
 
line 3, the transgenic mice have greatly reduced numbers of
thymocytes, up to 10-fold less, in comparison with non-
transgenic littermates (Table I). Similarly, the numbers of
mature T cells in the spleen are also significantly reduced in
Figure 1. Upregulation of Bad expression during thymocyte apoptosis.
Total cell lysate from 107 thymocytes per lane was resolved by SDS
PAGE, Western blotted, and Bad expression detected by probing with
anti-Bad antibody. Cell lysate was prepared from thymocytes immediately
after removal of the thymus from C57 Bl/10 mice (Control, 0 h). Lysates
were also prepared from thymocytes 5 h after g-radiation, 5 h with 5 mM
dexamethasone, or 5 h in culture alone. The percent apoptosis in the
samples before cell lysate preparation is shown. The positive control for
Bad expression is a thymocyte lysate from a bad transgenic mouse; equal
numbers of cells were not added in this lane. Tubulin expression is a load-
ing control to show that each track contains approximately equivalent
amounts of protein.
Figure 2. bad transgene. (A) The mouse bad cDNA including a 59 HA
epitope was cloned into the EcoRI site of the human CD2 VA expression
vector. The SalI-XbaI fragment was then isolated for microinjection.
Western blot analysis of transgene expression in the two transgenic lines
studied was carried out using total cell extract of thymocytes. Equal
amounts of protein were loaded in each lane. (B) The blot was probed
with the 12CA5 mAb against HA, to detect the presence of the transgene
and (C) with a polyclonal anti-Bad antibody to compare the levels of en-
dogenous and transgenic Bad expression.
 
Table I.
 
bad Transgenic Mice Have Decreased Numbers
of Thymocytes
 
Total thymocyte numbers
Line 1 (6 wk) Line 3 (5 wk) Line 1 (4 wk)
 
bad
 
 transgenic 7.3 
 
3
 
 10
 
7
 
2.4 
 
3
 
 10
 
7
 
2.7 
 
3
 
 10
 
7
 
2.6 
 
3
 
 10
 
7
 
2.8 
 
3
 
 10
 
7
 
3.8 
 
3
 
 10
 
7
 
Nontransgenic 23 
 
3
 
 10
 
7
 
16 
 
3
 
 10
 
7
 
24 
 
3
 
 10
 
7
 
17 
 
3
 
 10
 
7
 
13 
 
3
 
 10
 
7
 
17 
 
3
 
 10
 
7 
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bad transgenic mice (data not shown). We then analyzed
the effect of bad on the different populations of T cells in
the thymus. Bad transgenic mice have greatly decreased
percentages of both CD42CD81 and CD41CD82 T cells
compared to nontransgenic mice (Fig. 3 A). Similar analysis
of splenocytes shows a substantial decrease in the propor-
tion of mature single positive (SP) T cells present in the bad
transgenic mice compared to controls (Fig. 3 B). Unlike for
TCR-a/b T cells, the significance of apoptosis in TCR-
g/d T cell development is unknown. We found that the
percentage of g/d T cells relative to the percentage of a/b
T cells in the CD42CD82 thymocytes of bad transgenic
mice was virtually unchanged relative to nontransgenic
thymuses (Fig. 3 C). Similarly, the total number of TCR-
g/d expressing cells in the thymus of bad transgenic mice is
not significantly different. Therefore, the effect of the bad
transgene on mature T cell production is restricted to
TCR-a/b bearing T cells rather than TCR-g/d T cells.
Bad Accelerates Apoptosis in a Manner Rescuable by Bcl-2.
We investigated the effect of bad overexpression in re-
sponse to apoptotic stimuli in T cells from bad transgenic
mice. We used several stimuli that have been shown to in-
duce apoptotic cell death. These included stimuli blocked
by Bcl-2, i.e., g-radiation and dexamethasone as well as
CD95-induced apoptosis which is not blocked by Bcl-2
but can be blocked by Bcl-xL (33, 34). Thymocytes from
bad transgenic mice and nontransgenic littermates were
treated with apoptotic stimuli, samples harvested at various
time points, and the amount of apoptosis determined by
propidium iodide staining of DNA followed by flow cy-
tometry analysis (26). Previous studies have shown that
overexpression of Bad alone in a cell line has no effect on
apoptosis (14). However, we show that thymocytes from
bad transgenic mice placed in culture have significantly in-
creased levels of apoptosis by as early as 4 h (Fig. 4 A). After
6 h of incubation there is .10-fold increase in the propor-
tion of cells undergoing apoptosis compared with the non-
transgenic mice. Therefore, overexpression of bad alone is
able to greatly accelerate the rate of apoptosis of thy-
mocytes in culture.
We tested various apoptotic stimuli to determine the ac-
tion of Bad in different apoptosis pathways. g-radiation in-
duces p53-dependent apoptosis through DNA damage, and
thymocytes in particular are highly sensitive to this form of
damage (35). The level of apoptosis in bad transgenic and
nontransgenic thymocytes was determined after treatment
with 5 Gy of g-radiation. By 4 h after irradiation, ,5% of
nontransgenic thymocytes are apoptotic as opposed to
.50% of bad transgenic thymocytes (Fig. 4 B). Dexa-
methasone-induced, p53-independent apoptosis was also
tested. The bad transgenic thymocytes were also signifi-
cantly more sensitive to dexamethasone-induced apoptosis
than nontransgenic thymocytes (Fig. 4 C). Therefore,
overexpression of bad sensitizes primary T cells to the Bcl-
2–dependent pathways of apoptosis induced by g-radiation
and dexamethasone.
CD95-mediated apoptosis has been known to occur via
a different pathway to that of DNA damage and glucocor-
ticoid-induced apoptosis (36) and has been shown to be in-
dependent of both Bcl-2 (6) and Bax (27). Thymocytes
were treated with 1 mg/ml of anti-CD95 antibody (Jo2)
and the level of apoptosis determined at various time
Figure 3. bad transgenic mice have decreased numbers of mature a/b T cells. (A) FACS®
analysis of CD4 vs. CD8 expression of thymocytes and (B) splenocytes from bad transgenic
and nontransgenic littermates. Cells were stained with specific anti-CD4 and anti-CD8 anti-
bodies. The subpopulations of CD81CD41, CD41CD82, and CD42CD81 T cells are gated
and their percentages given. (C) Histogram indicating the percentage of TCR-g/d express-
ing cells within the CD42CD82 thymocytes of bad transgenic and nontransgenic littermates.
The numbers in parentheses indicate the total number of TCR-g/d expressing cells in each
thymus.579 Mok et al.
points. Anti-CD95 treatment clearly accelerates apoptosis
in bad transgenic thymocytes (Fig. 4 D). Therefore, it appears
that Bad is also capable of acting in a Bcl-2–independent
apoptotic pathway. This may well be due to its interaction
with Bcl-xL since Bcl-xL is known to block CD95-induced
apoptosis in primary T cells (33, 34).
Bad has been shown previously to interact with Bcl-2
(14). Therefore, we tested whether overexpression of bcl-2
in T cells could rescue the proapoptotic effect of bad over-
expression. We crossed bcl-2 transgenic mice to bad trans-
genic mice and determined the amount of apoptosis after in
vitro culture of thymocytes from the resulting mice. The
presence of the bcl-2 transgene in bad transgenic mice lead
to a partial rescue in the level of apoptosis upon culture of
thymocytes from mice containing only the bad transgene
(Fig. 5). However, the bcl-2 transgene did not restore the
number of thymocytes to wild-type levels, which may be
due to the level of the transgenic Bcl-2 protein being insuf-
ficient to bind all the transgenic HA Bad protein or the
Bad–Bcl-2 interaction being too weak to overcome the ef-
fects of bad overexpression (14).
Bad Perturbs T Cell Selection. To further analyze the ac-
tion of Bad on T cell development we generated mice con-
taining the bad transgene, an F5 TCR transgene (37) on the
RAG-12/2 background (38) as well as being homozygous
for the H-2b MHC haplotype. The F5 TCR recognizes an
influenza virus nucleoprotein–derived peptide in the con-
text of MHC class I H-2Db (39). These mice allow the ac-
tion of bad on the selection of a unique TCR specificity to
be examined in the absence of endogenous TCR gene re-
arrangements.
Figure 4. bad transgenic mice exhibit increased levels of apoptosis. (A) Total thymocytes from bad and nontransgenic (WT) littermates were cultured
in vitro for 6 h. Duplicate samples were analyzed from each mouse at each time point indicated. Each value represents the mean 6 range of the duplicate
determinations. Two individual mice per phenotype are represented. The (1) indicates the presence of the apoptotic stimulus and the (2) indicates its
absence. The numbers 1 and 3 refer to mice from the independent bad transgenic lines 1 and 3, respectively. Similar studies were carried out after treatment
with either (B) 5 Gy g-irradiation, (C) 5 mM dexamethasone, or (D) anti-CD95 antibody, together with untreated controls. Similar results were obtained
in three independent experiments.
Figure 5. bcl-2 expression partially rescues thymocytes from the pro-
apoptotic effects of bad. Total thymocytes from bad, bcl-2, and bad/bcl-2
heterozygous double transgenic mice were cultured in vitro over 8 h and
samples processed at 4-h intervals to determine the percentage of apop-
totic cells.580 Action of Bad on T Cell Apoptosis
As shown in Fig. 6 A and Table II, overexpression of bad
causes a dramatic decrease in both total thymic cellularity
and mature T cell production. Thymocytes and splenocytes
were analyzed after staining with antibodies against CD4,
CD8, and Vb11 (which recognizes the F5 TCR b chain)
(Fig. 6). The presence of bad in the F5/RAG-12/2 mice
results in a decrease in total thymocyte numbers from 19.8 3
107 to 5.4 3 107 and a reduction in CD42CD8hi mature T
cell numbers .10-fold (Table II). This is also reflected in a
decrease in the percentage of CD42CD8hi T cells produced
(Fig. 6 A). In the thymus of F5/RAG-12/2 mice, TCR
expression is upregulated (Vb11hi) during the transition
from CD4hiCD8hi, through CD4loCD8hi to CD42CD8hi
thymocytes, as shown by the shaded region in Fig. 6 A
(37). However, the presence of the bad transgene greatly
diminishes this upregulation, particularly in the transitional
CD4loCD8hi population (Fig. 6 A). The effect on mature T
cells is also seen in the periphery, where the percentage of
CD42CD8hi cells is reduced by more than twofold in the
bad transgenic mice (Fig. 6 B). It should be noted that the
level of Vb11 expression on CD42CD8hi peripheral T cells
is similar in bad transgenic and nontransgenic mice. This in-
dicates that the action of Bad is during selection and those
T cells which pass this point are similar in transgenic and
nontransgenic mice. We conclude that Bad, as a result of its
proapoptotic action, can directly affect the process of T cell
selection.
Akt Kinase Activity Regulates Bad Function in Primary T
Cells. Recent studies in an IL-3–dependent cell line and
in primary neurons have shown that Akt kinase has a direct
role in the phosphorylation of Bad and hence regulation of
the action of Bad (22, 23). The data suggest that Bad is
downstream of the PI-3-K/Akt pathway and is a central
player in the interaction between signal transduction and
the cell death machinery. Therefore, we examined whether
Akt kinase activity could regulate Bad-induced apoptosis in
primary T cells. Thymocytes from bad transgenic mice and
nontransgenic mice were cultured with either wortmannin,
an irreversible inhibitor, or LY294002, a competitive in-
hibitor of PI-3-K (40, 41). Inhibition of PI-3-K blocks Akt
kinase activity (42) and thus should block the phosphoryla-
tion of Bad (23). Therefore, if Akt regulates Bad-induced
apoptosis in T cells, the addition of LY294002 and wort-
mannin to bad transgenic thymocytes should inhibit Bad
phosphorylation. This will block the dissociation of Bad
Table II. F5/RAG-12/2/bad Mice Have Decreased Total 
Numbers of Thymocytes as well as Decreased Numbers of Mature 
CD81CD42 Thymocytes
Total thymo-
cyte number
CD42CD8hi
(mature thymocytes)
F5/RAG-12/2/Control 19.8 3 107 6 4.4 2.4 3 107 6 0.6
F5/bad/RAG-12/2 5.4 3 107 6 2.5 0.20 3 107 6 0.04
(n 5 4)
Figure 6. bad perturbs T cell selection. Thymocytes and splenocytes
were isolated from F5/bad/RAG-12/2 and F5/RAG-12/2 mice, and
subsequently stained with antibodies specific for CD8, CD4, and Vb11.
(A) Dot plots showing CD8 vs. CD4 expression on thymocytes with the
percentages of each subpopulation indicated. Vb11 expression in the581 Mok et al.
from Bcl-xL or Bcl-2 and hence have a proapoptotic action
which should be reflected in increased apoptosis of the thy-
mocytes. To evaluate the effect of PI-3-K inhibitors on
Bad-induced apoptosis, thymocytes from bad transgenic and
nontransgenic mice were cultured with LY294002 (20 mM)
or wortmannin (2 mM) and the levels of apoptosis mea-
sured against time. The experiments were carried out using
thymocytes from both line 1 and line 3 of bad transgenic
mice. Wortmannin significantly accelerated apoptosis in
bad transgenic thymocytes from both lines while having no
effect on nontransgenic thymocytes (Fig. 7 A). Similarly,
LY294002 accelerated Bad-induced apoptosis while having
no effect on nontransgenic thymocytes (Fig. 7 B). The lack
of effect of PI-3-K inhibitors on apoptozing nontransgenic
thymocytes during the time course studied is most likely
due to the low levels of Bad present in normal thymocytes
(Figs. 1 and 2 C).
To confirm that the effect of the PI-3-K inhibitors was
on Akt activation, we directly measured the Akt kinase ac-
tivity in thymocytes from bad transgenic mice in the pres-
ence or absence of the inhibitors. Akt kinase activity was
assayed by in vitro kinase assay after Akt immunoprecipita-
tion using histone H2B as substrate (23). Akt kinase ac-
tivity was measured in thymocytes from bad transgenic and
nontransgenic mice after in vitro culture. The constitutive
level of Akt kinase activity (0 h) is much higher in bad
transgenic mice than in nontransgenic mice (Fig. 8 A). This
high level of Akt kinase activity falls as the level of apopto-
sis increases with time, whereas the level of Akt kinase ac-
tivity in the wild type remains negligible. In the presence
of wortmannin the rate of decrease of Akt activity is greater
in the bad transgenic thymocytes than without wortmannin
(Fig. 8 B). For example, as determined by densitometry,
the level of Akt kinase activity is almost halved in bad trans-
genic thymocytes after 2–3 h in culture in the presence of
wortmannin. Thus, the effect of PI-3-K inhibitors in accel-
erating Bad-induced apoptosis appears to be mediated via
the reduction of Akt kinase activity. However, we were
surprised to discover that bad transgenic thymocytes have a
significantly elevated level of constitutive Akt kinase activ-
ity. This suggests that, although Bad is biochemically down-
stream of Akt, elevated levels of Bad can influence the level
of Akt activity, possibly by a paracrine/autocrine feedback
mechanism.
Bad Overexpression Enhances Cell Cycle Progression and Up-
regulates IL-2 Production after T Cell Activation. We then
analyzed the functional consequences of bad overexpression
on the PI-3-K/Akt pathway. The signaling pathway in-
volving PI-3-K/Akt has been shown to have a role in reg-
gated regions, CD81CD41, CD8hiCD4lo, and CD81CD42, is shown in
the histograms. The shaded region represents F5/RAG-12/2 mice and
the solid line represents F5/bad/RAG-12/2 mice. (B) Similarly for sple-
nocytes from mice of the same genotypes, CD4 vs. CD8 expression is
shown in the dot plots with a gate on the CD81CD42 population. Vb11
expression in the CD81CD42 cells is shown in the histogram below.
Figure 7. Inhibition of Akt accelerates bad-induced apoptosis. (A) Total thymocytes from bad transgenic mice and control littermates of both trans-
genic lines were cultured in vitro in the presence of 2 mM wortmannin (irreversible inhibitor of PI-3-K) and the percentage of apoptotic cells at each
time point was determined as before. (B) Similar studies were carried out with 20 mM LY294002 (competitive inhibitor of PI-3-K).582 Action of Bad on T Cell Apoptosis
ulating progression through the cell cycle of T cells (43).
We measured the DNA content of thymocytes from bad
transgenic and nontransgenic littermates by propidium io-
dide staining. In nontransgenic mice the vast majority
(z90%) of thymocytes are resting in G0/G1 while ,10%
are actively progressing through the cell cycle and found in
S phase (Table III). However, in bad transgenic mice the
fraction of thymocytes that are in the S phase of the cell cy-
cle is two- to threefold higher (Table III). The proportion
of cells in G0/G1 is consequently reduced in bad transgenic
thymuses. Therefore, overexpression of bad is sufficient to
increase the number of T cells entering the cell cycle. This
is a similar effect to that found in bax transgenic mice (27)
and the opposite to that found in bcl-2 transgenic mice, where
the number of thymocytes in S phase is reduced (44, 45).
Activation of T cells is associated with their progression
through the cell cycle. Activated T cells produced IL-2,
which directly promotes cell cycle entry (46). Having ob-
served that bad can promote cell cycle progression, we ex-
amined whether bad could affect the production of IL-2 in
mature T cells after activation via anti-CD3. A precedent
for this comes from studies on T cells from bcl-2 transgenic
mice which show that bcl-2 overexpression significantly de-
creases IL-2 production (44). Therefore, we purified T
cells from the lymph nodes of bad transgenic, bcl-2 trans-
genic, and nontransgenic mice, activated the T cells using
serial dilutions of plate bound anti-CD3 antibody, and as-
sayed the production of IL-2. The bcl-2 transgenic T cells
produced much less IL-2 than those from nontransgenic
mice, as reported previously (44). However, the bad trans-
genic T cells produced substantially more IL-2 than T cells
from nontransgenic mice (Fig. 9). This effect on IL-2 pro-
duction was not apparent after costimulation of purified bad
transgenic T cells with anti-CD28 as well as serially diluted
anti-CD3 antibody (data not shown). This may be due to
the fact that anti-CD28 strongly induces bcl-xL expression
(47), which would then bind the excess Bad present.
The action of Bad on cell cycle progression and cytokine
production suggests that a feedback mechanism may exist
whereby T cells may try to accommodate the elevated lev-
els of Bad. For example, elevated Bad leads to increased
protective cytokine production upon activation which
could act in an autocrine manner to enhance survival. This
could also enhance Akt kinase activity and enhance cell cy-
cle entry.
Discussion
Bad Acts as a Proapoptotic Molecule in Primary T Cells.
The Bcl-2 family member, Bad, has emerged as a key regu-
lator of apoptosis from studies on hematopoietic cell lines
(41). We have examined the function of Bad in regulating
apoptosis of primary T cells both in culture and in vivo.
Our initial observation was that the level of Bad expression
is greatly upregulated in thymocytes exposed to apoptotic
stimuli such as g-radiation or dexamethasone. To deter-
mine whether elevated Bad was an effector mechanism in
T cell apoptosis and how Bad might function in this con-
text, we generated mice overexpressing a bad transgene in
Figure 8. Akt kinase activity in bad thymocytes is constitutively higher
and is inhibited by wortmannin. Total cell lysates were prepared from
thymocytes of bad transgenic mice and control littermates which had been
cultured for up to 4 h. Akt was immunoprecipitated and an in vitro kinase
assay was carried out using histone H2B as substrate. (A) The constitutive
(0 h) level of kinase activity and the activity versus time of the nontrans-
genic control is shown in the left panel, and that of the bad transgenic
mice in the right panel. (B) Akt kinase activity of bad transgenic thy-
mocytes is shown in the absence (left) or presence (right) of 2 mM wort-
mannin over 4 h.
Table III. bad Transgenic Mice Have Increased Numbers of 
Thymocytes in S Phase of the Cell Cycle
Percentage of thymocytes in cycle
Percent G0/G1 phase Percent S phase
bad 67.0 6 6.4 26.9 6 4.7
Nontransgenic 86.9 6 3.7 9.1 6 1.8
(n 5 12)
Figure 9. bad transgenic T cells produce higher levels of IL-2 on stim-
ulation with anti-CD3 antibody. T cells purified from the lymph nodes of
bad, bcl-2 transgenic mice, and nontransgenic mice were activated with
serial dilution of cross-linked anti-CD3 antibody. IL-2 production was
determined by CTLL assay and [3H]thymidine incorporation.583 Mok et al.
their T cells. Overexpression of bad is sufficient to acceler-
ate apoptosis in primary thymocytes from bad transgenic
mice maintained in culture, confirming its proapoptotic
nature. The excess Bad may well act by binding the avail-
able endogenous Bcl-2 and Bcl-xL, thus preventing their
function and accelerating apoptosis.
Thymocytes from bad transgenic mice also exhibit signif-
icantly increased levels of apoptosis after treatment with
low dose g-radiation, dexamethasone, and anti-CD95 anti-
body. These data indicate that Bad is capable of acting in
multiple apoptotic pathways. Bcl-2 has been shown to pro-
tect thymocytes against g-radiation and dexamethasone (9,
10) and Bax has the opposite effect, accelerating apoptosis
in response to these stimuli (32). Surprisingly, our data also
indicate that Bad is capable of influencing CD95-mediated
apoptosis, which occurs via a distinct pathway from DNA
damage and glucocorticoid-induced apoptosis (6). This ef-
fect of Bad is contrary to the action of some of the other
members of the Bcl-2 family. Bcl-2 has been shown to
have no effect on CD95-induced apoptosis in the lym-
phoid cells of bcl-2 transgenic mice (6) and Bax is unable to
accelerate CD95-mediated apoptosis in thymocytes trans-
genic for bax (27). We propose that the effect of Bad on
CD95-induced apoptosis is a result of its preferred interac-
tion with Bcl-xL (14). Bcl-xL has been shown to inhibit
apoptosis in the CD95 pathway (33, 34). We suggest that
overexpressing Bad leads to sequestration of all the endoge-
nous Bcl-xL, thus removing its protective function. In ad-
dition, excess unbound Bad may also actively accelerate
apoptosis in response to anti-CD95. This effect of Bad
could be related to the structural properties of Bad which
distinguish it from other Bcl-2 family members. It lacks the
COOH-terminal signal anchor sequence found in other
Bcl-2–related molecules apart from Bid (14, 18), suggesting
that Bad may not exist as an integral membrane protein.
The homology of its BH1 and BH2 domains to other Bcl-2
family members is limited (14). Although Bad may prefer-
entially bind Bcl-xL (14), using thymocytes from mice car-
rying both bad and bcl-2 transgenes, we have shown that
Bcl-2 can, at least partially, rescue the proapoptotic action
of Bad. This is at variance with the previously reported lack
of effect of Bad on Bcl-2 in a transfected IL-3–dependent
cell line (14). However, the rescue is only partial, which
may be due to stoichiometry or a reflection of the weak in-
teraction between Bad and Bcl-2.
The Action of Bad on T Cell Development. Bad transgenic
mice have a significantly smaller thymus compared to non-
transgenic littermates. The bad transgenic mice have only
15–20% of the thymocytes present in the control mice.
This effect correlates with the increased apoptosis found in
bad transgenic thymocytes. We also found reduced num-
bers of mature SP thymocytes which suggests that overex-
pressing bad interferes with the process of T cell selection.
It is also significant to note that the effect of Bad is only
found on maturation of T cells bearing a/b TCRs rather
than those bearing g/d TCRs. This is consistent with
known differences between a/b and g/d T cells, including
differences in their developmental pathway in the thymus,
the absence of positive selection in g/d T cell develop-
ment, and the mechanisms of antigen recognition by g/d T
cells (48, 49).
We sought to clarify the action of Bad on T cell devel-
opment using MHC class I restricted F5 TCR transgenic
mice on a RAG-12/2 background to produce mice whose
T cells express a unique TCR. Expression of bad in F5/
RAG-12/2 mice reduced the size of the thymus almost
fourfold (Table II). The number of CD42CD8hi T cells
produced is reduced 10-fold and the upregulation of TCR
(Vb11) expression in the CD4loCD8hi population nor-
mally associated with maturation is also reduced. There-
fore, Bad can act directly on the processes involved in T
cell selection. The impairment of both T cell maturation
and TCR upregulation suggest that Bad can disrupt posi-
tive selection or enhance negative selection. Further analy-
sis is required to determine if Bad acts in one or both of
these ways. It should be noted that the mature T cells
found in the spleen of bad transgenic mice, although dimin-
ished in numbers, do exhibit comparable levels of TCR
expression to nontransgenic controls. This indicates that
the thymocytes that do mature and enter the periphery are
normal and that the effect of Bad is mainly on the develop-
mental and selection processes which occur in the thymus.
Biochemical Regulation of Bad and Consequences for T Cell
Function. Akt kinase can directly regulate the action of
Bad through phosphorylation of serine 136 (22). Akt activ-
ity itself is regulated via PI-3-K (24). Phosphorylation of
Bad results in loss of its proapoptotic function and leads to
binding to 14-3-3 (19, 21). Our experiments confirm that
Akt kinase activity is directly involved in the regulation of
Bad in primary T cells. By using the specific PI-3-K inhib-
itors wortmannin and LY294002, we demonstrate that in-
hibition of Akt kinase activity leads to an increase in the
level of apoptosis of bad transgenic thymocytes in culture.
The most likely explanation for this effect is that inhibition
of Akt kinase leads to increased levels of unphosphorylated
Bad which is free to exert its proapoptotic effect either by
binding Bcl-xL/Bcl-2 or through its direct action. In fur-
ther support of this hypothesis, we directly show that wort-
mannin decreases Akt kinase activity in bad transgenic thy-
mocytes, concomitant with the increase in thymocyte
apoptosis. Hence the Akt–Bad regulation pathway acts in
primary T cells, although as Akt only phosphorylates one of
the two phosphorylated serines on Bad (22) it is likely that
Akt-independent regulation of Bad may also take place in
primary T cells. We also observed that the constitutive
level of Akt kinase activity in bad thymocytes is significantly
higher than that in control littermates. Akt activity has
been shown to be upregulated by IL-2 and this effect is PI-
3-K mediated (50). Furthermore, wortmannin is able to
block this upregulation of Akt activity (40, 41). This raises
the possibility that bad overexpression has the downstream
effect of modulating, directly or indirectly, IL-2 production
which activates Akt by a feedback loop and so enhances
cell survival to compensate for elevated level of Bad.
The bad transgene increases the number of thymocytes in
S phase of the cell cycle by two- to threefold. This is a sim-584 Action of Bad on T Cell Apoptosis
ilar effect to that shown for another Bcl-2 family member,
Bax (27). In the case of Bax, we have shown previously
that the effect on cell cycle is a direct one, impinging on
the molecules that regulate G1–S transition. The phosphor-
ylation of Bad has been shown to be regulated by growth
factors (19, 23, 22) and furthermore, one of the key factors
which influences the G1–S transition in T cells is cytokines,
such as IL-2 (46). We have demonstrated that IL-2 is pro-
duced at much higher levels in activated bad transgenic T
cells than in control T cells. Therefore, it is possible that
the modulation of IL-2 production, or of other cytokines,
increases cell cycle progression of bad transgenic thymo-
cytes. The same modulation may then act in a paracrine or
autocrine manner to activate the signaling pathway involv-
ing PI-3-K leading to the greatly increased Akt kinase ac-
tivity found in bad transgenic T cells. Conversely, bcl-2
transgenic T cells have greatly decreased IL-2 production
in comparison to control T cells. The suppression of IL-2
production by Bcl-2 in activated T cells (44) has been
shown to be due to its ability to block the calcineurin-
dependent nuclear translocation of NFAT, a transcription
factor which is required for the induction of IL-2 gene ex-
pression (51). Therefore, we suggest that the effect of Bad
on IL-2 induction is mediated either by antagonizing the
suppressive effect of Bcl-2 on NFAT translocation via cal-
cineurin or that Bad itself can enhance NFAT translocation
by some novel mechanism. Whichever precise mechanism
is the correct one, the net effect is that bad overexpression
allows hyperinduction of IL-2 expression after activation.
The evidence of Bad upregulation during apoptosis and
the data from bad transgenic mice identify Bad as a poten-
tial key regulator of T cell apoptosis. Further experiments
will involve the use of T cells from bad transgenic mice to
examine the effect of Bad overexpression on the signal
transduction pathways implemented after T cell activation.
This will determine whether the action of Bad in elevating
cytokine production is due to an effect on a discrete point
in the signaling pathway, a generalized effect, or if it is lim-
ited to the NFAT-calcineurin junction. Other studies will
address the manner in which Bad acts on T cell selection, to
increase negative selection or reduce positive selection (13).
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